Rights Issue 2022
Neola Medical AB (publ) (“the Company”) has, due to legal restrictions, limited the availability of this part of the website. We therefore ask you to take note of the following information and provide the following confirmation each time you wish to access these web pages. Please note that the terms and conditions below may be changed or updated, and it is therefore important that you read them each time you visit this site.
The information on this part of the Company’s website is not intended for, and may not, directly or indirectly, in whole or in part, be accessed by or distributed or disseminated to persons residing or located in the United States (including its territories and possessions, any state of the United States and the District of Columbia) (“United States”), Canada, Japan, Australia, Hong Kong, New Zealand, Switzerland, South Africa or any other jurisdiction where such action is subject in whole or in part to legal restrictions, or would require additional prospectuses, registration or other measures than those required by Swedish law. The information on the Websites does not constitute an offer of shares, subscription rights, paid-up subscribed shares or shares issued by the Company (“Securities”) to any person in the said jurisdictions. Nor may the information on the web pages be transmitted or reproduced in a manner that is contrary to such restrictions or would impose such requirements.
No Securities have been or will be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state or other jurisdiction of the United States and may not be offered, subscribed, exercised, pledged, sold, resold, assigned, delivered or otherwise transferred, directly or indirectly, in or into the United States, except pursuant to any exemptions accepted by the Company.
The Company reserves the right, subject to any relevant exemption, to accept subscriptions from a person located or resident in a jurisdiction where participation would otherwise require additional prospectuses, registration, or other measures other than those required by Swedish law.
Within the European Economic Area (“EEA”), no offer to the public of Securities will be made in any country other than Sweden. In other member states of the European Union (“EU”), such an offer may only be made in accordance with the exemptions in the Prospectus Regulation (EU) 2017/1129 (the “Prospectus Regulation”). In other EEA countries that have implemented the Prospectus Regulation into national law, such an offer may only be made in accordance with the exemption in the Prospectus Regulation and in accordance with any relevant implementing measure. In other EEA countries that have not implemented the Prospectus Regulation into national law, such an offer may only be made in accordance with the applicable exemption in national law.
To access the information on this part of the Company’s website, all persons must first ensure that they are not subject to any legal restrictions limiting their ability to access the information on this part of the Company’s website.
We therefore ask you to confirm that you are resident, or located, outside the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Switzerland, South Africa or any other jurisdiction where such action is subject in whole or in part to legal restrictions, or would require additional prospectus, registration or other action other than that required by Swedish law and are entitled to access the information on these web pages without restriction by law or regulation and without the requirement that any additional action be taken by the Company. We also ask you to confirm that you have read the information, terms and restrictions above and that you agree to abide by them.
Information about Neola Medical’s Rights Issue 2022
Here we collect information linked to the rights issue.
The ones who are registered as a shareholder in the share register maintained by Euroclear on behalf of the Company on the record date, September 30, has preferential rights to subscribe for new shares in relation to the number of shares held on the record date.
Each share held on the record date entitles the shareholder to one (1) subscription right. One (1) subscription right entitles subscription for two (2) new shares.
A maximum of 42,099,960 shares, corresponding to approximately 54,7 million SEK.
SEK 1.30 per share. Brokerage fee is not charged.
The record date at Euroclear for determining who has the right to receive subscription rights in the Rights Issue is September 30, 2022. The last day for trading in the Company’s shares including the right to receive subscription rights in the Rights Issue is September 28, 2022. First day of trading in the Company’s shares excluding rights to obtain subscription rights in the Rights Issue is 29 September 2022.
Subscription of new shares with the support of subscription rights must take place by means of a simultaneous cash payment during the period from October 4, 2022 to October 18, 2022. During this period, notification of the subscription of shares can also be made without the support of subscription rights. The Board of Directors of the Company reserves the right to extend the subscription period, which, if relevant, will be announced by the Company via press release no later than the last day of the subscription period, October 18, 2022. The press release will be available on Neola Medical’s website, https://www.neolamedical.se/.
Trading in subscription rights
Trading in subscription rights takes place on Nasdaq First North Growth Market during the period from October 4, 2022 to October 13, 2022 under the ticker NEOLA TR. The ISIN code for the subscription rights is SE0018689044. Shareholders must apply directly to their bank or other administrator with the necessary permission to carry out the purchase and sale of subscription rights. Subscription rights that are not intended to be used for subscription in the Rights Issue must be sold no later than 13 October 2022 or used for subscription of shares no later than 18 October 2022 in order not to become invalid and lose their value. Upon sale of subscription rights, both primary and subsidiary subscription rights are transferred to the new holder of the subscription right. Subscription rights which are acquired during the aforementioned trading period give, during the subscription period, the same right to subscribe for new shares as the subscription rights shareholders receive based on their holdings in the Company on the record date.
Unused subscription rights
Subscription rights which have not been sold by October 13, 2022 at the latest or been used to subscribe for shares by October 18, 2022 at the latest will be booked from all VP accounts without compensation. No special notification takes place when subscription rights are cancelled.
Trade with BTA
Trading in BTA will take place on the Nasdaq First North Growth Market from October 4th until the Swedish Companies Registration Office (Bolagsverket) has registered the Rights Issue and BTA has been converted into shares, which is expected to take place around week 45. Securities institutions with the necessary permits are at your service with buying and selling BTA.
The Rights Issue means, if fully subscribed, that the number of shares in the Company increases from 21,049,980 shares to 63,149,940 shares, which corresponds to a dilution of approximately 67 percent of the total number of shares.